Skip to main content
SpringerLink
Log in

In Silico Design of Anticancer Peptides

  • Protocol
  • First Online:
Proteomics for Drug Discovery

Part of the book series: Methods in Molecular Biology ((MIMB,volume 1647))

Abstract

In the past few years, small peptides having anticancer properties have emerged as a potential avenue for cancer therapy. Compared to current anti-cancer chemotherapeutic drugs (or small molecules), anticancer peptides (ACPs) have numerous advantageous properties, such as high specificity, low production cost, high tumor penetration, ease of synthesis and modification. However, in wet lab setups, identification and characterization of novel ACPs is a time-consuming and labor-intensive process. Therefore, in silico designing of anticancer peptides is beneficial, prior to their synthesis and characterization. This approach is less time consuming and more cost-effective. In this chapter, we discuss a web-based tool, AntiCP (http://crdd.osdd.net/raghava/anticp/), for designing ACPs.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution

Institutional subscriptions

References

  1. Siegel RL, Miller KD, Jemal A (2016) Cancer statistics, 2016. CA Cancer J Clin 66:7–30. doi:10.3322/caac.21332

    Article  PubMed  Google Scholar 

  2. Mayne ST, Playdon MC, Rock CL (2016) Diet, nutrition, and cancer: past, present and future. Nat Rev Clin Oncol. doi:10.1038/nrclinonc.2016.24

  3. Wu D, Gao Y, Qi Y et al (2014) Peptide-based cancer therapy: opportunity and challenge. Cancer Lett 351:13–22. doi:10.1016/j.canlet.2014.05.002

    Article  CAS  PubMed  Google Scholar 

  4. Peer D, Karp JM, Hong S et al (2007) Nanocarriers as an emerging platform for cancer therapy. Nat Nanotechnol 2:751–760. doi:10.1038/nnano.2007.387

    Article  CAS  PubMed  Google Scholar 

  5. Amit D, Hochberg A (2010) Development of targeted therapy for bladder cancer mediated by a double promoter plasmid expressing diphtheria toxin under the control of H19 and IGF2-P4 regulatory sequences. J Transl Med 8:134. doi:10.1186/1479-5876-8-134

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  6. Kang TH, Mao C-P, He L et al (2012) Tumor-targeted delivery of IL-2 by NKG2D leads to accumulation of antigen-specific CD8+ T cells in the tumor loci and enhanced anti-tumor effects. PLoS One 7:e35141. doi:10.1371/journal.pone.0035141

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  7. Bidwell GL (2012) Peptides for cancer therapy: a drug-development opportunity and a drug-delivery challenge. Ther Deliv 3:609–621

    Article  CAS  PubMed  Google Scholar 

  8. Thundimadathil J (2012) Cancer treatment using peptides: current therapies and future prospects. J Amino Acids 2012:967347. doi:10.1155/2012/967347

    Article  PubMed  PubMed Central  Google Scholar 

  9. Vlieghe P, Lisowski V, Martinez J, Khrestchatisky M (2010) Synthetic therapeutic peptides: science and market. Drug Discov Today 15:40–56. doi:10.1016/j.drudis.2009.10.009

    Article  CAS  PubMed  Google Scholar 

  10. Mader JS, Hoskin DW (2006) Cationic antimicrobial peptides as novel cytotoxic agents for cancer treatment. Expert Opin Investig Drugs 15:933–946. doi:10.1517/13543784.15.8.933

    Article  CAS  PubMed  Google Scholar 

  11. Gaspar D, Veiga AS, Castanho MARB (2013) From antimicrobial to anticancer peptides. A review. Front Microbiol 4:294. doi:10.3389/fmicb.2013.00294

    Article  PubMed  PubMed Central  Google Scholar 

  12. Chu H-L, Yip B-S, Chen K-H et al (2015) Novel antimicrobial peptides with high anticancer activity and selectivity. PLoS One 10:e0126390. doi:10.1371/journal.pone.0126390

    Article  PubMed  PubMed Central  Google Scholar 

  13. Okumura K, Itoh A, Isogai E et al (2004) C-terminal domain of human CAP18 antimicrobial peptide induces apoptosis in oral squamous cell carcinoma SAS-H1 cells. Cancer Lett 212:185–194. doi:10.1016/j.canlet.2004.04.006

    Article  CAS  PubMed  Google Scholar 

  14. Risso A, Braidot E, Sordano MC et al (2002) BMAP-28, an antibiotic peptide of innate immunity, induces cell death through opening of the mitochondrial permeability transition pore. Mol Cell Biol 22:1926–1935

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  15. Lehmann J, Retz M, Sidhu SS et al (2006) Antitumor activity of the antimicrobial peptide magainin II against bladder cancer cell lines. Eur Urol 50:141–147. doi:10.1016/j.eururo.2005.12.043

    Article  CAS  PubMed  Google Scholar 

  16. Hui L, Leung K (2002) Chen HM The combined effects of antibacterial peptide cecropin A and anti-cancer agents on leukemia cells. Anticancer Res 22:2811–2816

    CAS  PubMed  Google Scholar 

  17. Kim S, Kim SS, Bang YJ et al (2003) In vitro activities of native and designed peptide antibiotics against drug sensitive and resistant tumor cell lines. Peptides 24:945–953

    Article  CAS  PubMed  Google Scholar 

  18. Ohtake T, Fujimoto Y, Ikuta K et al (1999) Proline-rich antimicrobial peptide, PR-39 gene transduction altered invasive activity and actin structure in human hepatocellular carcinoma cells. Br J Cancer 81:393–403. doi:10.1038/sj.bjc.6690707

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  19. Fang X-Y, Chen W, Fan J-T et al (2013) Plant cyclopeptide RA-V kills human breast cancer cells by inducing mitochondria-mediated apoptosis through blocking PDK1-AKT interaction. Toxicol Appl Pharmacol 267:95–103. doi:10.1016/j.taap.2012.12.010

    Article  CAS  PubMed  Google Scholar 

  20. Cao Q, Lin Z-B (2006) Ganoderma lucidum polysaccharides peptide inhibits the growth of vascular endothelial cell and the induction of VEGF in human lung cancer cell. Life Sci 78:1457–1463. doi:10.1016/j.lfs.2005.07.017

    Article  CAS  PubMed  Google Scholar 

  21. Kim SE, Kim HH, Kim JY et al (2000) Anticancer activity of hydrophobic peptides from soy proteins. Biofactors 12:151–155

    Article  CAS  PubMed  Google Scholar 

  22. Kozłowska K, Nowak J, Kwiatkowski B, Cichorek M (1999) ESR study of plasmatic membrane of the transplantable melanoma cells in relation to their biological properties. Exp Toxicol Pathol Off J 51:89–92. doi:10.1016/S0940-2993(99)80074-8

    Article  Google Scholar 

  23. Sok M, Sentjurc M, Schara M (1999) Membrane fluidity characteristics of human lung cancer. Cancer Lett 139:215–220

    Article  CAS  PubMed  Google Scholar 

  24. Ellerby HM, Arap W, Ellerby LM et al (1999) Anti-cancer activity of targeted pro-apoptotic peptides. Nat Med 5:1032–1038. doi:10.1038/12469

    Article  CAS  PubMed  Google Scholar 

  25. Hariharan S, Gustafson D, Holden S et al (2007) Assessment of the biological and pharmacological effects of the alpha nu beta3 and alpha nu beta5 integrin receptor antagonist, cilengitide (EMD 121974), in patients with advanced solid tumors. Ann Oncol 18:1400–1407. doi:10.1093/annonc/mdm140

    Article  CAS  PubMed  Google Scholar 

  26. Gregorc V, De Braud FG, De Pas TM et al (2011) Phase I study of NGR-hTNF, a selective vascular targeting agent, in combination with cisplatin in refractory solid tumors. Clin Cancer Res 17:1964–1972. doi:10.1158/1078-0432.CCR-10-1376

    Article  CAS  PubMed  Google Scholar 

  27. Khalili P, Arakelian A, Chen G et al (2006) A non-RGD-based integrin binding peptide (ATN-161) blocks breast cancer growth and metastasis in vivo. Mol Cancer Ther 5:2271–2280. doi:10.1158/1535-7163.MCT-06-0100

    Article  CAS  PubMed  Google Scholar 

  28. Deplanque G, Madhusudan S, Jones PH et al (2004) Phase II trial of the antiangiogenic agent IM862 in metastatic renal cell carcinoma. Br J Cancer 91:1645–1650. doi:10.1038/sj.bjc.6602126

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  29. Sharma A, Kapoor P, Gautam A et al (2013) Computational approach for designing tumor homing peptides. Sci Rep 3:1607. doi:10.1038/srep01607

    Article  PubMed  PubMed Central  Google Scholar 

  30. Gupta S, Kapoor P, Chaudhary K et al (2013) In silico approach for predicting toxicity of peptides and proteins. PLoS One 8:e73957. doi:10.1371/journal.pone.0073957

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  31. Gautam A, Chaudhary K, Kumar R et al (2013) In silico approaches for designing highly effective cell penetrating peptides. J Transl Med 11:74. doi:10.1186/1479-5876-11-74

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  32. Sharma A, Singla D, Rashid M, Raghava GPS (2014) Designing of peptides with desired half-life in intestine-like environment. BMC Bioinformatics 15:282. doi:10.1186/1471-2105-15-282

    Article  PubMed  PubMed Central  Google Scholar 

  33. Kumar R, Chaudhary K, Singh Chauhan J et al (2015) An in silico platform for predicting, screening and designing of antihypertensive peptides. Sci Rep 5:12512. doi:10.1038/srep12512

    Article  PubMed  PubMed Central  Google Scholar 

  34. Tyagi A, Kapoor P, Kumar R et al (2013) In silico models for designing and discovering novel anticancer peptides. Sci Rep 3:2984. doi:10.1038/srep02984

    Article  PubMed  Google Scholar 

  35. Vijayakumar S, PTV L (2014) ACPP: a Web server for prediction and design of anti-cancer peptides. Int J Pept Res Ther 21:99–106. doi:10.1007/s10989-014-9435-7

    Article  Google Scholar 

Download references

Acknowledgement

AntiCP server was developed by Raghava’s group (http://www.imtech.res.in/raghava/) at CSIR-IMTECH, India.

Author information

Authors and Affiliations

  1. Department of Pathology, School of Medicine, University of Virginia, 345 Crispell Dr., MR6-B524, Charlottesville, VA, 22908, USA

    Shailesh Kumar & Hui Li

  2. Department of Biochemistry and Molecular Genetics, School of Medicine, University of Virginia, Charlottesville, VA, 22908, USA

    Hui Li

Authors
  1. Shailesh Kumar
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Hui Li
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Hui Li .

Editor information

Editors and Affiliations

  1. Department of Biological Sciences, Virginia Tech, Blacksburg, Virginia, USA

    Iulia M. Lazar

  2. Department of Pharmaceutical Sciences, School of Pharmacy, Southern Illinois University Edwardsville, Edwardsville, Illinois, USA

    Maria Kontoyianni

  3. ImmunoGen, Waltham, Massachusetts, USA

    Alexandru C. Lazar

Rights and permissions

Reprints and permissions

Copyright information

© 2017 Springer Science+Business Media LLC

About this protocol

Cite this protocol

Kumar, S., Li, H. (2017). In Silico Design of Anticancer Peptides. In: Lazar, I., Kontoyianni, M., Lazar, A. (eds) Proteomics for Drug Discovery. Methods in Molecular Biology, vol 1647. Humana Press, New York, NY. https://doi.org/10.1007/978-1-4939-7201-2_17

Download citation

  • DOI: https://doi.org/10.1007/978-1-4939-7201-2_17

  • Published:

  • Publisher Name: Humana Press, New York, NY

  • Print ISBN: 978-1-4939-7200-5

  • Online ISBN: 978-1-4939-7201-2

  • eBook Packages: Springer Protocols

Publish with us

Policies and ethics

Search

Navigation